Category Archives: Muddled Media

Alkermes, ALKS5461, and the FDA

Alkermes late yesterday announced that the third of the ALKS 5461 antidepressant Phase III trials had yielded positive results for the high dose, utilizing an SPCD trial design and an alternative parsing of the MADRS as the primary endpoint. The … Continue reading

Posted in Biotech, Muddled Media | Tagged , , , , , , | Leave a comment

Kerrisdale Provides Less than Sage Advice

On March 23, a number of NeuroPerspective subscribers and sources forwarded to us a ‘report’ prepared by Kerrisdale Capital on SAGE Therapeutics. Subheaded ‘Overhyped Lead Drug Headed for Failure,’ it gave the illusion of a detailed, seemingly well-researched critique of … Continue reading

Posted in BioFollies, Biotech, Muddled Media | Tagged , , , , | Leave a comment

Valeant Needs Autopsy, Not CPR

Neurogram/August 2015: “This brings us to Valeant Pharmaceuticals. We despise Valeant, a company that routinely treats acquired companies like poachers who have machine-gunned an elephant in the veldt, stripping the tusks while leaving the carcass to rot in the tropical … Continue reading

Posted in Big Pharma, BioFollies, Biotech, Muddled Media | Tagged , | 1 Comment

Aducanumab: Less Than Meets The Eye

The beta-amyloid target in Alzheimer’s has become, to put it politely, somewhat tarnished over the past several years. AN-1792, bapineuzumab, solanezumab, gantenerumab, plus several BACE and gamma-secretase inhibitors/modulators, have combined to form a conga-line of clinical disappointments, undulating its way … Continue reading

Posted in BioFollies, Biotech, Muddled Media, Science | Tagged , , | Leave a comment

A Momentary Lapse of Reason*

*Floyd, P.  1987 Every now and then, pharma/biotech companies do things that suggest that they had experienced a transient ischemic attack against their better judgment. Today there were two such events in the news: 1) Biogen-Idec and BIIB037 Biogen-Idec is … Continue reading

Posted in BioFollies, Biotech, Muddled Media | Tagged , , , | Leave a comment

The Golden Age of Neuroscience

We were surprised and thrilled, as so many were, to find out from the Wall St Journal that the “Golden Age of Neuroscience Has Arrived” (Michio Kaku, 8/20/14). We hadn’t even received an email alert. Apparently, we are now able … Continue reading

Posted in BioFollies, Muddled Media, Science | 1 Comment

NeuralStem and the ‘Right-To Try’

Colorado has recently passed ‘Right-to-Try’ (RTT) legislation permitting companies to offer experimental treatments for fatal diseases that have not been FDA approved—and the requirement of payment is permitted if the Company so chooses. The criterion is that they have reached … Continue reading

Posted in BioFollies, Biotech, Muddled Media | Tagged , , , | Leave a comment